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Semaphorin 4D (SEMA4D, CD100) and its receptor
plexin-B1 are broadly expressed in cancer and expres-
sion correlates with invasive disease in several human
tumors. SEMA4D normally functions to regulate the
motility and differentiation of multiple cell types, includ-
ing those of the immune, vascular, and nervous systems.
In the setting of cancer, we describe a novel immuno-
modulatory function of SEMA4D in regulating immune
cell infiltration and anti-tumor activity. Activity is
enhanced in preclinical studies when combined with
other immunotherapies, including immune checkpoint
blockade inhibition.
Methods
In vitro effects of SEMA4D and in vivo blockade of
SEMA4D with monoclonal murine antibody was evaluated
in preclinical syngeneic models – tumor growth and
immune-mediated responses were characterized to evalu-
ate mechanism of action. The safety and tolerability of
humanized anti-SEMA4D antibody VX15/2503 was
assessed in Phase I clinical trials in oncology.
Results
SEMA4D restricts migration of macrophage cell lines in
vitro. Strong expression of SEMA4D at the invasive
margins of actively growing in vivo tumors modulates
the infiltration and spatial distribution of leukocytes in
the tumor microenvironment (TME). Antibody neutrali-
zation of SEMA4D disrupts this gradient and facilitates
recruitment of activated antigen presenting cells and
T lymphocytes into the TME, shifting the balance of
cytokines toward increased Th1 and reduced immuno-
suppressive cytokines. This orchestrated change in the
tumor architecture was associated with durable tumor
rejection and immunologic memory in preclinical mod-
els. Importantly, the immunomodulatory activity of
anti-SEMA4D antibody can be further enhanced by
combination with other immunotherapies, including
immune checkpoint inhibition and chemotherapy. Strik-
ingly, the combination of anti-SEMA4D antibody with
antibody to CTLA-4 acts synergistically to promote com-
plete tumor rejection, with significant 58% increase in
tumor regression and maximal increase in survival, as
compared to monotherapy.
Treatment with anti-SEMA4D antibodies was well toler-
ated in nonclinical and clinical studies, including comple-
tion of a Phase I prospective multiple ascending dose trial
in patients with advanced refractory solid tumors. Weekly
doses of between 0.3 and 20 mg/kg were administered; no
MTD was determined. Patients with the longest duration
of treatment, 48-55 weeks, included colorectal, breast, and
a papillary thyroid patient, who had a partial response by
RECIST. Progression free survival correlated with elevated
baseline lymphocyte counts, supporting an immune
mediated mechanism of action for VX15/2503.
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Conclusion
Inhibition of SEMA4D represents a novel mechanism
and therapeutic strategy to promote functional immune
infiltration into the tumor and inhibit tumor progres-
sion. A Phase Ib/IIa trial of combination therapy with
immune checkpoint inhibition is planned.
Authors’ details
1Vaccinex, Inc, Rochester, NY, USA. 2David Geffen School of Medicine at
UCLA, Los Angeles, CA, USA. 3University of California at Los Angeles Medical
Center, Los Angeles, CA, USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P220
Cite this article as: Evans et al.: Antibody blockade of semaphorin 4D
breaks down barriers to enhance tumoricidal immune infiltration and
supports rational immunotherapy combinations. Journal for
ImmunoTherapy of Cancer 2015 3(Suppl 2):P220.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Evans et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P220
http://www.immunotherapyofcancer.org/content/3/S2/P220
Page 2 of 2
